BURLINGAME, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced the closing of its initial public offering of 5,000,000 shares of its common stock at a price of $4.00 per share resulting in gross proceeds of $20 million before customary underwriting discounts and offering-related expenses. Pulse Biosciences granted the underwriters a 45-day over-allotment option to purchase up to an additional 750,000 shares at the initial public offering price. All of the shares were offered by Pulse Biosciences. The shares commenced trading on the NASDAQ Capital Market on May 18, 2016.
MDB Capital Group and Feltl and Company acted as the joint book-running managers for the offering.
A registration statement relating to the securities sold was declared effective by, the Securities and Exchange Commission on May 13, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pulse Biosciences
Pulse Biosciences is a medical device company developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling, or NPES. NPES has been shown in pre-clinical data to provide effective local tumor control and to initiate an adaptive immune response. Pulse Biosciences intends to deploy its NPES platform across a variety of applications, including human oncology, dermatology, aesthetics and other minimally invasive applications where current ablation modalities do not provide comparable benefits. More information is available at www.pulsebiosciences.com.
About MDB Capital Group
MDB Capital Group finances development stage companies that possess meaningful technology which has the potential to impact large commercial markets and benefit humanity. MDB maximizes the value of these technology companies by helping position them to be the dominant leader in their technology domain and connecting them with a community of high-quality investors. For more information, visit www.mdb.com.
About Feltl and Company
Feltl and Company is a full service securities broker and investment bank with a focus on serving the investment requirements of their valued individual, institutional, and corporate clients. Feltl and Company strives to deliver thoughtful advice which markedly benefits their clients in areas they care about. For decades, they have dedicated their efforts to providing the best investment services available. For more information, visit www.feltl.com.
Contact: Brian Dow SVP & Chief Financial Officer firstname.lastname@example.org
Source:Pulse Biosciences, Inc.